Fig. 2 | Signal Transduction and Targeted Therapy

Fig. 2

From: First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study

Fig. 2

Tumor response. a Waterfall plot of maximum percent change in tumor size from baseline in each patient as measured by Response Evaluation Criteria in Solid Tumors (version 1.1). b Longitudinal percentage change in tumor size from baseline. c Time on treatment. Among the patients who received dose 2, one patient did not undergo post-baseline response evaluation and thus was not included in Fig. 2a, b

Back to article page